Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intensive Transcranial Magnetic Stimulation for Negative Symptoms in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02127879
Recruitment Status : Unknown
Verified May 2014 by Tomáš Svěrák, Masaryk University.
Recruitment status was:  Recruiting
First Posted : May 1, 2014
Last Update Posted : May 5, 2014
Sponsor:
Collaborator:
Masaryk University
Information provided by (Responsible Party):
Tomáš Svěrák, Masaryk University

Brief Summary:
The main purpose of this study is to determine whether intensive repetitive transcranial magnetic stimulation (I-rTMS) is effective in the treatment of negative symptoms in schizophrenia patients and whether it has a positive influence on their cognitive functions, social functions, quality of life, alpha frequency and cortical silent period changes. Also, this study should provide data about safety and tolerability this I-rTMS treatment in schizophrenia patients.

Condition or disease Intervention/treatment Phase
Schizophrenia Device: Transcranial Magnetic Stimulation Device: Transcranial Magnetic Stimulation with sham coil Not Applicable

Detailed Description:

Patients undergo 5x EEG from safety and research reasons during the study. Stimulation coil location (left DLPFC) is determined by magnetic resonance imaging (1,5T, 3D- TFE, voxel size 1 x 1 x 1 mm, Intera MR scanner) and stereotactic neuronavigation (Brainsight Frameless).

Patients are evaluated by several psychiatric scales. Positive and negative symptom scale (PANSS) is applied before the first stimulation, at the end of every stimulation day and two weeks after the last stimulation (a total 6). Other psychiatric evaluations used are Clinical global impression (CGI), Sheehan disability scale (SDS), Personal and social performance scale (PSP) and Montgomery-Asberg Depression Scale (MADRS), Calgary depression scale for schizophrenia (CDSS); (MADRS and CDSS are for the exclusion of depression). These scales were used only before the start of the first stimulation, after its completion and two weeks after the last test.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: High-frequency Repetitive Transcranial Magnetic Stimulation for Negative Symptoms in Schizophrenia: The Double-blind Sham-controlled Study
Study Start Date : May 2014
Estimated Primary Completion Date : October 2016
Estimated Study Completion Date : October 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: Transcranial Magnetic Stimulation
Active Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
Device: Transcranial Magnetic Stimulation
16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
Other Name: Magstim Rapid 2

Sham Comparator: Transcranial Magnetic Stimulation with sham coil
Sham coil Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
Device: Transcranial Magnetic Stimulation with sham coil
16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
Other Name: Magstim Rapid 2 with sham coil




Primary Outcome Measures :
  1. Change from baseline in negative symptoms measured by Negative scale in Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Baseline, Week 3 ]

Secondary Outcome Measures :
  1. Number of Participants with Serious and Non-Serious Adverse Events [ Time Frame: Up to 5 weeks ]
    Patients undergoing five times EEG during the study for safety reasons. The researcher assigns patients on their health and mental condition by Visual Analogous Scale every day before and after rTMS stimulation.


Other Outcome Measures:
  1. Change from baseline in quality of life in the Quality of Life questionaire (SQUALA) at week 3 [ Time Frame: At baseline, Week 3 ]
  2. Change from baseline in cognitive functions measured by Verbal learning test, Rey- Osterrieth complex figure, D2 test, Repeating numbers memory test, London tower test, Verbal fluency test at week 3 [ Time Frame: Baseline, Week 3 ]
    Verbal learning test testing memory (based on Rey Auditory Verbal Learning Test), Rey- Osterrieth complex figure testing testing sensomotoric and visuospatial skills, D2 test testing attention, Repeating numbers memory test testing working memory, London Tower test testing executive functions and Verbal fluency test testing verbal fluency and recalling of words

  3. Change from baseline in social functions measured by Sheehan Disability Scale (SDS) and by Personal and Social Performance Scale (PSP) at week 3 [ Time Frame: Baseline, Week 3 ]
  4. Change from baseline in global clinical improvement measured by Clinical Global Impression (CGI) at week 3 [ Time Frame: Baseline, Week 3 ]
  5. Change from baseline in alpha frequency measured by EEG at week 3 [ Time Frame: Baseline, Week 3 ]
  6. Change from baseline in cortical silent period measured by transcranial magnetic stimulation at week 3 [ Time Frame: Baseline, Week 3 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed an informed consent, the patient must be able and willing to participate in a research study,
  • Undergo an examination by international neuropsychiatric questionnaire MINI - PLUS to confirm the diagnosis of schizophrenia
  • schizophrenic illness duration longer than one year,
  • have a stable and consistent drug treatment at least two weeks prior the rTMS treatment
  • persistent negative symptoms without further psychiatric comorbidity (like depression, mania, anxiety disorders, personality disorders, etc.) in the foreground of the illness
  • The sum of negative scores in the range Positive and negative symptom score (PANSS) must be 20 points or higher and at least one item from the area of negative symptoms (N1-N7) must be ≥ 4 points (at least moderate, clinically significant symptoms),
  • improvement in negative symptom-sum (measuring by PANSS) must be 10% or lower during the last two weeks before rTMS stimulation.

Exclusion Criteria:

  • involuntary stay in a psychiatric clinic during the recruitment of patients;
  • clinically relevant unstable medical conditions;
  • factors incompatible with the use of rTMS, such as pacemakers, heart pumps and other metal implants;
  • history of epileptic seizures or the presence of epileptic activity documented on the basis of EEG
  • current treatment with anticonvulsant acting drugs such as anticonvulsants, benzodiazepines (10mg/D or less of diazepam or equivalent dosage of other benzodiazepines);
  • lack of cognitive skills for participation;
  • clinically relevant psychiatric comorbidity (any other axis 1 diagnosis) detected using MINI Plus, including the current abuse of drugs and alcohol;
  • heart attack or traumatic head injury in the anamnesis
  • Patient unable to undergo a brain MRI
  • Acute risk of suicide;
  • knowledge of Czech language at a level that does not allow fill the required test battery;
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02127879


Contacts
Layout table for location contacts
Contact: Tomáš Svěrák, Mgr. +420737504353 362515@mail.muni.cz

Locations
Layout table for location information
Czech Republic
Departement of psychiatry, University Hospital Recruiting
Brno, Czech Republic, 62500
Contact: Tomáš Svěrák, Mgr.    +420737504353    362515@mail.muni.cz   
Sub-Investigator: Michaela Mayerová, MUDr.         
Principal Investigator: Radovan Přikryl, Prof.         
Principal Investigator: Tomáš Svěrák, Mgr.         
Sponsors and Collaborators
Brno University Hospital
Masaryk University
Investigators
Layout table for investigator information
Principal Investigator: Tomáš Svěrák, Mgr. Brno University Hospital
Study Director: Radovan Přikryl, Prof. Brno University Hospital

Layout table for additonal information
Responsible Party: Tomáš Svěrák, Mgr., Masaryk University
ClinicalTrials.gov Identifier: NCT02127879     History of Changes
Other Study ID Numbers: TSRPMMLA1
61300 ( Other Identifier: Department of Psychiatry, Faculty of Medicine, Masaryk University, Brno, Czech Republic )
First Posted: May 1, 2014    Key Record Dates
Last Update Posted: May 5, 2014
Last Verified: May 2014

Keywords provided by Tomáš Svěrák, Masaryk University:
Repetitive Transcranial Magnetic Stimulation
Schizophrenia
Negative symptoms
Intensive
Transcranial Magnetic Stimulation, Repetitive

Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders